254 related articles for article (PubMed ID: 28372871)
1. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations.
Salani R; Khanna N; Frimer M; Bristow RE; Chen LM
Gynecol Oncol; 2017 Jul; 146(1):3-10. PubMed ID: 28372871
[TBL] [Abstract][Full Text] [Related]
2. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations.
Salani R; Backes FJ; Fung MF; Holschneider CH; Parker LP; Bristow RE; Goff BA
Am J Obstet Gynecol; 2011 Jun; 204(6):466-78. PubMed ID: 21752752
[TBL] [Abstract][Full Text] [Related]
3. Improving quality and decreasing cost in gynecologic oncology care. Society of gynecologic oncology recommendations for clinical practice.
Rimel BJ; Burke WM; Higgins RV; Lee PS; Lutman CV; Parker L
Gynecol Oncol; 2015 May; 137(2):280-4. PubMed ID: 25735256
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for Follow-up Care for Gynecologic Cancer Survivors.
Elit L; Reade CJ
Obstet Gynecol; 2015 Dec; 126(6):1207-1214. PubMed ID: 26551194
[TBL] [Abstract][Full Text] [Related]
5. Positron Emission Tomography/Computed Tomography for Gynecologic Malignancies.
Oldan JD; Patel PS
Obstet Gynecol Surv; 2016 Sep; 71(9):545-56. PubMed ID: 27640609
[TBL] [Abstract][Full Text] [Related]
6. [Value of colposcopy in diagnosing recurrent gynecologic malignancies].
Zhang WH
Zhonghua Zhong Liu Za Zhi; 1990 Nov; 12(6):438-40. PubMed ID: 2076640
[TBL] [Abstract][Full Text] [Related]
7. Incorporating laparoscopy in the practice of a gynecologic oncology service: actual impact beyond clinical trials data.
Ghezzi F; Cromi A; Uccella S; Siesto G; Zefiro F; Bolis P
Ann Surg Oncol; 2009 Aug; 16(8):2305-14. PubMed ID: 19459012
[TBL] [Abstract][Full Text] [Related]
8. Fine-needle aspiration cytology versus core biopsies in the evaluation of recurrent gynecologic malignancies.
Malmström H
Gynecol Oncol; 1997 Apr; 65(1):69-73. PubMed ID: 9103393
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance.
Bristow RE; Purinton SC; Santillan A; Diaz-Montes TP; Gardner GJ; Giuntoli RL
Gynecol Oncol; 2006 Nov; 103(2):709-13. PubMed ID: 16797686
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer.
Armstrong A; Otvos B; Singh S; Debernardo R
Gynecol Oncol; 2013 Dec; 131(3):503-7. PubMed ID: 24060416
[TBL] [Abstract][Full Text] [Related]
11. Results of a prospective study with comparison of clinical, endosonographic, computed tomography, magnetic resonance imaging and pathologic staging of advanced gynecologic carcinoma and recurrence.
Houvenaeghel G; Delpero JR; Rosello R; Resbeut M; Viens P; Jacquemier J; Noirclerc M; Guerinel G
Surg Gynecol Obstet; 1993 Sep; 177(3):231-6. PubMed ID: 8356495
[TBL] [Abstract][Full Text] [Related]
12. Laparoscopic training and practice in gynecologic oncology among Society of Gynecologic Oncologists members and fellows-in-training.
Frumovitz M; Ramirez PT; Greer M; Gregurich MA; Wolf J; Bodurka DC; Levenback C
Gynecol Oncol; 2004 Sep; 94(3):746-53. PubMed ID: 15350368
[TBL] [Abstract][Full Text] [Related]
13. Financial burden of gynecologic-cancer survivors associated with attendance in a surveillance program at a tertiary care hospital in Thailand.
Suprasert P; Manopunya M
Asian Pac J Cancer Prev; 2011; 12(7):1761-3. PubMed ID: 22126561
[TBL] [Abstract][Full Text] [Related]
14. [Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 72.4, SCC, 90 K].
Garzetti GC; Di Lauro RM; Ciavattini A; Pallotta MR; Marchegiani F; Valensise H; Tranquilli AL; Arduini D; Romanini C
Ann Ostet Ginecol Med Perinat; 1991; 112(5):320-3. PubMed ID: 1817444
[TBL] [Abstract][Full Text] [Related]
15. Post treatment surveillance of type II endometrial cancer patients.
Zakhour M; Li AJ; Walsh CS; Cass I; Karlan BY; Rimel BJ
Gynecol Oncol; 2013 Dec; 131(3):609-12. PubMed ID: 24051222
[TBL] [Abstract][Full Text] [Related]
16. [General and specific laboratory parameters within the scope of tumor after-care in gynecologic malignancies and breast cancer].
Kreienberg R
Gynakologe; 1989 Feb; 22(1):55-62. PubMed ID: 2653979
[No Abstract] [Full Text] [Related]
17. Feasibility and economic impact of a clinical pathway for pap test utilization in Gynecologic Oncology practice.
Santillan A; Govan L; Zahurak ML; Diaz-Montes TP; Giuntoli RL; Bristow RE
Gynecol Oncol; 2008 Jun; 109(3):388-93. PubMed ID: 18405946
[TBL] [Abstract][Full Text] [Related]
18. Hormone replacement therapy in gynecologic cancer survivors: why not?
Ibeanu O; Modesitt SC; Ducie J; von Gruenigen V; Agueh M; Fader AN
Gynecol Oncol; 2011 Aug; 122(2):447-54. PubMed ID: 21474167
[TBL] [Abstract][Full Text] [Related]
19. Permanent interstitial reirradiation with 198Au as salvage therapy for low volume recurrent gynecologic malignancies: a single institution experience.
Brabham JG; Cardenes HR
Am J Clin Oncol; 2009 Aug; 32(4):417-22. PubMed ID: 19451799
[TBL] [Abstract][Full Text] [Related]
20. The value of colposcopy in follow-up care of the treated gynecologic oncology patient.
Blythe JG
Gynecol Oncol; 1983 Apr; 15(2):186-9. PubMed ID: 6832633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
